GLSI Greenwich LifeSciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1799788 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-27.9%
TTM EPS YoY-14.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-107,371.7%
ROA-481.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets129.6%
Debt / equity—
Current ratio0.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.55x
Accruals ratio-217.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $17.22M | $15.48M | $7.70M | $6.48M | $3.56M |
| SG&A expense | $2.23M | $2.16M | $1.63M | $1.56M | $1.04M |
| Operating income | -$19.45M | -$17.64M | -$9.33M | -$8.04M | -$4.60M |
| Net income | -$19.36M | -$17.41M | -$8.89M | -$7.83M | -$4.57M |
| EPS (basic) | -1.43 | -1.34 | -0.69 | -0.61 | -0.35 |
| EPS (diluted) | -1.43 | -1.34 | -0.69 | -0.61 | -0.35 |
| Weighted avg. shares (diluted) | 13.53M | 13.01M | 12.85M | 12.91M | 12.94M |
| Balance sheet | |||||
| Cash & equivalents | $6.18M | $4.09M | $6.99M | $13.47M | $27.20M |
| Current assets | $6.18M | $4.09M | — | — | — |
| Intangibles | — | $1,779 | $5,391 | $9,003 | $12,615 |
| Total assets | $6.18M | $4.09M | $6.99M | $13.48M | $27.22M |
| Current liabilities | $5.82M | $3.19M | $294,406 | $262,905 | $385,172 |
| Total liabilities | $5.82M | $3.19M | $294,406 | $262,905 | $385,172 |
| Shareholders' equity | $353,217 | $908,626 | $6.70M | $13.21M | $26.83M |
| Shares outstanding | 14.30M | 13.15M | 12.85M | 12.85M | 13.15M |
| Cash flow statement | |||||
| Operating cash flow | -$9.91M | -$7.27M | -$6.48M | -$6.20M | -$4.29M |
| Financing cash flow | $12.00M | $4.37M | — | -$7.54M | $2.84M |
| Stock-based compensation | $6.80M | $7.25M | $2.38M | $1.74M | $660,582 |
| Share buybacks | — | — | — | $7.54M | — |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.